Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18400
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTverring, Jonas-
dc.contributor.authorVaara, Suvi T-
dc.contributor.authorFisher, Jane-
dc.contributor.authorPoukkanen, Meri-
dc.contributor.authorPettilä, Ville-
dc.contributor.authorLinder, Adam-
dc.date2017-10-18-
dc.date.accessioned2018-08-30T05:58:47Z-
dc.date.available2018-08-30T05:58:47Z-
dc.date.issued2017-10-18-
dc.identifier.citationAnnals of intensive care 2017; 7(1): 105-
dc.identifier.issn2110-5820-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18400-
dc.description.abstractBACKGROUND: Sepsis-related acute kidney injury (AKI) accounts for major morbidity and mortality among the critically ill. Heparin-binding protein (HBP) is a promising biomarker in predicting development and prognosis of severe sepsis and septic shock that has recently been proposed to be involved in the pathophysiology of AKI. The objective of this study was to investigate the added predictive value of measuring plasma HBP on admission to the intensive care unit (ICU) regarding the development of septic AKI. METHODS: We included 601 patients with severe sepsis or septic shock from the prospective, observational FINNAKI study conducted in seventeen Finnish ICUs during a 5-month period (1 September 2011-1 February 2012). The main outcome measure was the development of KDIGO AKI stages 2-3 from 12 h after admission up to 5 days. Statistical analysis for the primary endpoint included construction of a clinical risk model, area under the receiver operating curve (ROC area), category-free net reclassification index (cfNRI) and integrated discrimination improvement (IDI) with 95% confidence intervals (95% CI). RESULTS: Out of 511 eligible patients, 101 (20%) reached the primary endpoint. The addition of plasma HBP to a clinical risk model significantly increased ROC area (0.82 vs. 0.78, p = 0.03) and risk classification scores: cfNRI 62.0% (95% CI 40.5-82.4%) and IDI 0.053 (95% CI 0.029-0.075). CONCLUSIONS: Plasma HBP adds predictive value to known clinical risk factors in septic AKI. Further studies are warranted to compare the predictive performance of plasma HBP to other novel AKI biomarkers.-
dc.language.isoeng-
dc.subjectAcute kidney injury-
dc.subjectBiomarker-
dc.subjectHeparin-binding protein-
dc.subjectRisk model-
dc.subjectSepsis-
dc.titleHeparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury.-
dc.typeJournal Article-
dc.identifier.journaltitleAnnals of intensive care-
dc.identifier.affiliationDivision of Infection Medicine, Department of Clinical Sciences, Lund University, BMC B14, 221 84, Lund, Sweden-
dc.identifier.affiliationDivision of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland-
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Intensive Care, Lapland Central Hospital, Rovaniemi, Finland-
dc.identifier.doi10.1186/s13613-017-0330-1-
dc.identifier.orcid0000-0003-0939-6673-
dc.identifier.pubmedid29047023-
dc.type.austinJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.